Leary S E, Griffin K F, Garmory H S, Williamson E D, Titball R W
Medical Countermeasures Department, CBD, Porton Down, Salisbury, Wiltshire, SP4 0JQ, U.K.
Microb Pathog. 1997 Sep;23(3):167-79. doi: 10.1006/mpat.1997.0141.
A novel approach to making fusions of F1 and V antigens, which may be incorporated into a live recombinant vaccine for plague, was developed. The nucleotide sequences encoding Yersinia pestis V antigen (lcrV) and the mature form of F1 antigen (caf1) were amplified by PCR with primers which included tails. At the 3' end of caf1 and the 5' end of lcrV, the tails encoded one of three six- or eight-amino acid linkers or their complementary sequences. The DNA overlap in each linker region was used to prime a second PCR to generate three F1/V fusions, which were cloned into pUC18. The resulting plasmids expressed fusion proteins consisting of F1 and V antigens, separated by the linkers Gly-Ser-Ile-Glu-Gly-Arg, Ser-Ala-Pro-Gly-Thr-Pro or Ser-Ala-Pro-Gly-Thr-Pro-Ser-Arg. As shown by Western blotting of bacterial cell lysates with anti-V and anti-F1 sera, the level of expression and degree of degradation of the three fusion proteins was similar. To investigate the immunogenicity of F1/V, one of the plasmids, placFV6 which encoded the Gly-Ser-Ile-Glu-Gly-Arg linker, was electroporated into the attenuated Salmonella typhimurium strain SL3261 (aroA). Mice receiving two intravenous doses of 5 x 10(6) cfu SL3261/placFV6 developed serum anti-V and anti-F1 IgG titres, with similar IgG1:IgG2a isotype ratios, and T cell responses specific for V and F1 antigens. Six weeks after vaccination, mice were challenged subcutaneously with 7.4 x 10(2) or 7.4 x 10(4) LD50s of Y. pestis strain GB, and a significant degree of protection was demonstrated. These results demonstrate the potential of co-expressing Y. pestis antigens as fusion proteins to develop a live recombinant vaccine against plague.
开发了一种制备F1和V抗原融合体的新方法,该融合体可被纳入鼠疫活重组疫苗。用包含尾端的引物通过PCR扩增编码鼠疫耶尔森氏菌V抗原(lcrV)和成熟形式F1抗原(caf1)的核苷酸序列。在caf1的3'端和lcrV的5'端,尾端编码三种六或八个氨基酸接头之一或其互补序列。每个接头区域的DNA重叠部分用于引发第二次PCR,以产生三种F1/V融合体,将其克隆到pUC18中。所得质粒表达由F1和V抗原组成的融合蛋白,中间由接头Gly-Ser-Ile-Glu-Gly-Arg、Ser-Ala-Pro-Gly-Thr-Pro或Ser-Ala-Pro-Gly-Thr-Pro-Ser-Arg隔开。用抗V和抗F1血清对细菌细胞裂解物进行蛋白质印迹分析表明,三种融合蛋白的表达水平和降解程度相似。为了研究F1/V的免疫原性,将编码Gly-Ser-Ile-Glu-Gly-Arg接头的质粒placFV6电穿孔导入减毒鼠伤寒沙门氏菌菌株SL3261(aroA)。接受两剂静脉注射5×10⁶ cfu SL3261/placFV6的小鼠产生了血清抗V和抗F1 IgG滴度,IgG1:IgG2a同种型比例相似,并且对V和F1抗原具有特异性T细胞反应。接种疫苗六周后,小鼠皮下接种7.4×10²或7.4×10⁴ LD50的鼠疫耶尔森氏菌GB菌株,结果显示有显著程度的保护作用。这些结果证明了将鼠疫耶尔森氏菌抗原作为融合蛋白共表达以开发抗鼠疫活重组疫苗的潜力。